The European Medicines Agency has officially approved Afqlir, a biosimilar to Eylea, enhancing available treatment options for adults suffering from severe retinal conditions across the European Union.
Afqlir Targets Multiple Vision-Impairing Conditions
Afqlir, containing the active ingredient aflibercept, is designated for treating the ‘wet’ form of age-related macular degeneration (AMD), macular edema caused by retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization. Administered via intravitreal injections by qualified ophthalmologists, Afqlir offers a similar safety and efficacy profile to Eylea, the reference medicine it mirrors.
Clinical Efficacy and Safety Assured
Clinical trials involving 485 AMD patients revealed that Afqlir matches Eylea in improving visual acuity, with patients gaining an average of seven letters on standard eye tests after eight weeks. Side effects reported are comparable to those of Eylea, including conjunctival and retinal hemorrhages, reduced vision, and eye pain. Although serious risks like endophthalmitis and retinal detachment are rare, they underline the importance of professional administration.
- Offers a cost-effective alternative to Eylea, potentially expanding patient access
- Requires skilled administration to minimize serious side effects
- Supports treatment adherence with comparable efficacy to established therapies
- Continuous monitoring ensures ongoing safety and effectiveness
Afqlir’s authorization signifies a vital step forward in ophthalmic care, providing healthcare providers with an additional tool to manage debilitating eye conditions effectively. The introduction of Afqlir not only promises enhanced accessibility for patients but also encourages competition in the biosimilar market, which may lead to more affordable treatment options. Medical professionals must stay informed about the administration protocols and safety measures to maximize patient outcomes.
Patients diagnosed with AMD, diabetic macular edema, or other related conditions can now look forward to more treatment options, potentially reducing the burden of frequent and costly therapies. The European Medicines Agency’s decision highlights the commitment to expanding therapeutic choices while maintaining rigorous safety standards, ultimately aiming to improve the quality of life for individuals affected by severe vision impairment.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
